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Study of DNA Methylation by Tobacco-
Specific NNitrosamines
by Andre Castonguay,* Peter G. Foiles,* Neil Trushin,* and
Stephen S. Hecht*
An enzyme-linked immunosorbent assay (BA-ELISA) involving use ofbiotin-labeled anti-rabbit IgG and
avidin-labeled horseradish peroxidase was developed forthe measurement of06-methyl-2'-deoxyguanosine
(06-MedGuo). Up to 5 jg of methylated DNA was enzymatically hydrolyzed, and the extent of inhibition
of binding of immobilized 06-MedGuo-bovine serum albumin to rabbit anti-O6-MedGuo was measured.
Fifty percent inhibition of antigen-antibody binding was achieved with 2.5 pmole of of 06-MedGuo.
Separation of0-MedGuo from unmodified nucleosides by high-performance liquid chromatography (HPLC-
BA-ELISA) allowed detection of 700 fmole 06-MedGuo in 1 mg of DNA.
Among the tobacco-related carcinogens, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) is one
of the most potent. In F344 rats it induces nasal cavity, lung and liver tumors. Four hours after a single
IV injection ofNNK to F344 rats (87 mg/kg body weight), 0'-MedGuo was present in target organs (,umole
0'-MedGuo/mole dGuo) (nasal mucosa, 219; lung, 13.2; and liver, 34.5) but was not detectable in nontarget
organs. F344 rats receiving daily IP injections ofNNK (40 mg/kg body weight) for 14 days were sacrificed
24 hr after the last injection. The levels of (06-Medguo/dGuo) were 7.9 and 11.4 ,umole/mole in the nasal
mucosa and lung, respectively. In the liver no 06-MedGuo was detected, but 1050 ,umole of 7-MeGua/mole
Gua was measured by HPLC-fluorimetry. No DNA methylation was observed in the nasal mucosa or liver
ofF344 ratstreated withthe nicotine-derived carcinogenN'-nitrosonornicotine. Reduction ofthe carbonyl
of NNK is a major metabolic pathway, giving rise to 4-(methylnitrosamino)-1-(3-pyridyl)-1-butan-1-ol
(NNAI). Nasal mucosae were cultured in vitro with NNK or NNAI. After 1 hr, methylation at the 06-dGuo
and 7-dGuo sites were observed with NNK but not with NNAI. Methylation by NNAI after 24 hr was
associated with the conversion of NNAI to NNK. These results suggest that NNAI is not associated with
the activation of NNK to DNA methylating species.
Introduction
The high incidence of lung cancer among smokers is
well documented (1). Studies carried out duringthe last
10 years have shown that N-nitrosamines present in
tobacco smoke are relatively potent carcinogens in an-
imals. The same studies have suggested that N-nitro-
samines are important etiological factors in tobacco
smoking-related cancer (2). Among the 13 N-nitrosa-
mines detected in cigarette smoke, the tobacco-specific
N-nitrosamines are among the most abundant (3). Pro-
spective and retrospective studies have demonstrated
a link between snuff exposure and development of oral
cancer (4,5). At present, tobacco-specific N-nitrosa-
mines are the only carcinogens to have been isolated in
significant amounts from snuff (6). The levels of ab-
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sorption oftobacco components byrespiratory tract tis-
sues vary among smokers and intrinsic exposure to N-
nitrosamines during tobacco smoking is difficult to as-
sess. The tobacco-specific N-nitrosamines: N'-nitroso-
nornicotine (NNN) and 4-(methylnitrosamino)-1-(3-
pyridyl)-1-butanone (NNK) are derived from nicotine
and are metabolized rapidly invivo to metabolites iden-
tical to those of nicotine (2). Consequently, an assess-
ment ofexposuretonicotine-derivedN-nitrosamines by
quantification of their metabolites is not feasible.
However, alkylating species are generated only from
NNN and NNK, and levels oftheir persistent adducts
in DNAand proteins could be used as anindex ofhuman
exposure. Alternatively, assessment of repair of pro-
mutagenic DNA damage would measure the ability of
an individual to respond to carcinogen insults. The ob-
jective of the present study was to develop a safe, in-
expensive and sensitive method to measure the levels
of 06-methyl-2'-deoxyguanosine (06-MedGuo) in DNA
damaged by activated NNK.CASTONGUAY ET AL.
Materials and Methods
Chemicals
Synthesis ofNNK has been described, and its purity
was greater than 99% by high performance liquid chro-
matography (HPLC) (7). Sodiumborohydride reduction
of NNK gave 4-(methylnitrosamino)-1-(3-pyridyl)-bu-
tan-1-ol (NNAl) which was free of any traces of NNK
by reverse phase HPLC.
Culture ofRatNasalMucosa. Removal ofthe nasal
septum and its covering mucosa from the rat nasal cav-
ity and the culture technique of the septum have pre-
viously been described (8). Each septum was cultured
in a 35-mm culture dish (Falcon, Bethesda, MD) with 2
mL ofmedium containing either 100 jig of NNK or 101
,ug of NNAI/mL. After 1, 3, or 24 hr of culture, the
septa were harvested, and DNA was extracted from
three combined explants. The medium was harvested
and stored frozen. After filtration of the media, levels
of NNK and NNAI were measured by HPLC on an
octodecylsilane-bonded phase column (4.6 mm x 12.5
cm) as described elsewhere (9).
Rat Treatment with NNK and NNN. Five F344
rats each weighing approximately 280 g at the start of
the experiment were fed an NIH-07 diet (Ziegler Broth-
ers, Inc., Gardners, PA). They were injected IV with
a solution of NNK in 0.9% NaClIH2O (87 mg/kg body
weight) and decapitated 4 hr later. Livers, lungs, kid-
neys, esophagi, spleens, and hearts were excised and
immediately frozen over dry ice. The nasal cavity was
opened as described previously (8), and the mucosa cov-
ering the nasal septa and ethmoturbinates of the five
rats was scrapedoffwith ascalpel, pooled, andthe DNA
extracted as described previously (10).
Two F344 rats each weighing about 248 g received
each daily IP injections of 10 mg of NNN dissolved in
0.9% NaCl/H20 (20 mg/mL). Each rat received 14 in-
jections. Two other rats each received 10 mg of NNK
dissolved in 0.9% NaCI/H2O (20 mg/mL). The four rats
were exsanguinated by heart puncture 24 hr after the
last injection and the tissues mentioned above were ex-
cised and stored frozen until DNA extraction.
DNA samples were dissolved in 50 mM pH 7.2 Tris
HCI and DNA concentration was determined by fluor-
imetry (11). DNA was hydrolyzed according to the
method of Muller and Rajewsky (12).
Antibody Production and Purification
06-Methylguanosine (06-MeGuo) was conjugated to
bovine serum albumin (BSA) (Sigma, St. Louis, MO) or
keyhole limpet hemocyanin (KLH) (Calbiochem, La-
Jolla, CA) according to the method of Erlanger and
Beiser (13). New Zealand White rabbits were immu-
nized with an emulsion of the conjugate in complete
Freuds adjuvant (Calbiochem). The inoculum was in-
jected intradermally at approximately 20 sites on the
back ofeach rabbit. Four booster injections were given
at 8-week intervals. The 2-week bleeding after the last
booster injection was used in the present study. The
anti-O6-MedGuo antibodies were purified by affinity
chromatography as previously described for the anti-
06-ethyl-2'-deoxyguanosine (12).
BA-ELISA. The biotin-avidin enzyme-linked im-
munosorbent assay (BA-ELISA) was performed en-
tirely at room temperature in 96-well polystyrene
microtiter plates (Costar, Cambridge, MA). Each ex-
perimental value was determined in triplicate. The
amount of 06-MedGuo in a sample was determined by
the use of two standard curves. The first set of stan-
dards was used to measure the extent of inhibition of
binding ofthe primary antibody. The primary antibody
was diluted 1:1000. Further dilution of 4:5, 3:5 and 2:5
(corresponding to 20, 40 and 60% inhibition) served to
construct the standard curve. The second curve con-
sisted offive 6-fold dilutions of 06-MedGuo ranging be-
tween 0.1 and 25 pmole perwell and was used to equate
a given amount of 06-MedGuo with a given degree of
inhibition.
All wells were coated with 100 ,uL of06-MeGuo-BSA
at a concentration of 100 ng/mL in 50 mM Tris-HCl
buffer, pH 7.2, for 1 hr. After the removal of unbound
06-MeGuo-BSA, unoccupied protein bindingsites were
saturated by the addition of 100 ,LL of a 1% (w/v) so-
lution ofBSA in phosphate-buffered saline (PBS) for 30
min. Wells were then emptied and washed. The stan-
dard washing procedure was to rinse twice with PBS-
Tween (Sigma) (0.5 mL Tween 20/L PBS) and four times
with distilled water.
To set up the standard curves and experimental points
on the plate the following procedure was followed. All
reagents were diluted in PBS containing 0.1% (w/v)
BSA. 06-MedGuo standards orexperimental samples as
50 ,uL aliquots were added to the appropriate wells.
Wells used forthe primary antibody standards received
50 ,uL of diluent. Then wells containing 06-MedGuo
standards or experimental samples received 50 ,uL of
primary antibody (1:1000 dilution) and wells for the pri-
mary antibody standards received 50 pL of the appro-
priate antibody dilution. After incubation for 1 hr the
wells were emptied and washed with PBS as above.
Boundantibodywasdetectedwithbiotin-labeled anti-
rabbit IgG and avidin-labeled horseradish peroxidase
(Vector Labs, Burlingame, CA). Then 100 pL ofbiotin-
labeled antibody was incubated in the wells for 1 hr,
then removed and the wells washed as before; 100 ,uL
ofavidin-horseradish peroxidase was thenincubated for
30 min and washed as before. Enzyme activity was
measured with the substrate 1,2-diaminobenzene (o-
phenylenediamine, Sigma) at 500 ,ug/mL in 100 mM pH
6.2, phosphate buffer with 0.006% H202 (v/v) or with
2,2'-azino-di-(3-ethylbenzthiazoline sulfonic acid) diam-
monium salt (Sigma) at 200 ,ug/mL in 0.01 M phosphate
buffer, pH 6.0, with 0.001% H202 (v/v). Freshly pre-
pared substrate solution, 100 ,uL, was added to each
well and incubated until the absorbance was approxi-
mately 0.5. The reaction was stopped with 100 ,uL of2
N HCI. The absorbance was read at 490 nm for 1,2-
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diaminobenzene and at 405 nm for 2,2'-azino-di-(3-ethyl
benzthiazoline sulfonic acid) diammonium salt.
HPLC-BA-ELISA. The HPLC apparatus has been
described previously (14). Separation of deoxyribonu-
cleosides obtained by DNA hydrolysis was performed
witha pu-Bondapak-C15 column (4.9mm x 30cm) (Waters
Associated, Milford, MA) and with a gradient of 0 to
35% aqueous methanol in 50 min. The flow rate was 1
mL/min, and 1-mL fractions were collected. The frac-
tions were then lyophilyzed and reconstituted with 0.5
mL ofPBS. Individual fractions were then analyzed by
BA-ELISA as described above. The recovery of O-
MedGuo from HPLC vary between 70 and 100%. HPLC-
fluorimetry was carried out as described by Herron and
Shank (15).
Results
Figure 1 demonstrates the specificity and sensitivity
ofthe antibody used in the BA-ELISA for O6-MedGuo.
Fifty percent inhibition of antibody binding to immo-
bilized 06-MedGuo-BSA was achieved with 2.5 pmole
ofO6-MedGuo. Ifaprobability grid was used to plot the
inhibition curves, inhibition was linear between 15 and
85%. Fifteen percent inhibition is equivalent to 100 fmole
ofO6-MedGuo perwell. Since, ofthe compounds tested,
those containing a methyl group attached to the O6 po-
sition of guanine gave the highest levels of inhibition,
the specificity of the antibody was clearly directed to-
wards this group. N6-Methyl-2'-deoxyadenosine (N6-
MedAdo) was at least 1000-fold less efficient than O6-
MedGuo in inhibiting antigen-antibody binding. This in-
dicatesthattheantibodymayrecognizetheaminogroup
at the 2 position ofthe O6-MedGuo. The poor inhibition
of bindinf of 7-methyl-2'-deoxyguanosine (7-MedGuo)
versus 0 -MedGuo and of 3-methylguanine versus O6-
MeGua emphasizes the importance ofthe methyl group
being attached to the O6 position ofthe guanine moiety.
All five nucleosides naturally occurring in DNA were
found to inhibit binding only at concentrations 100,000-
fold higherthan those required for O6-MedGuo binding.
The maximum amount ofhydrolyzed DNA that could
be used perwell was 5 ,ug. This maximum limit sets the
lower limit ofmethylation which can be detected for 20
pmole O6-MedGuo/mg DNA. At 25 pg of DNA per cell
this level of methylation corresponds to 316,000 O6-
MedGuo residues per diploid genome (16). To circum-
vent this limitation, reverse-phase HPLC was used to
separate O6-MedGuo from unmodified and other meth-
ylated nucleosides. As shown in Figure 2 this technique
was used to measure the level of O6-MedGuo in DNA
isolated from the nasal mucosa of NNK treated rats.
Only those fractions having an elution volume equal to
that of 06-MedGuo gave substantial inhibition (64%) of
antibody bindinginthe BA-ELISA. By coupling HPLC
with the BA-ELISA the amount of DNA analyzed can
be increased from 5 ,ug to 1 mg or more. Following this
procedure a 1 mg sample containing as little as 700
fmole, which corresponds to 10,500 residues of 06_
MedGuo per diploid genome, can be analyzed in dupli-
cate (six wells).
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FIGURE 1. Inhibition of anti-06-MedGuo antibody binding to im-
mobilized 06-MeGuo-BSA byvarious nucleobases and nucleosides.
At a concentration of 100,000 pmole per well, 2'-deoxyadenosine
gave 39% inhibition, dGuo, adenine, and thymidine gave less than
20% inhibition and 2'-deoxycytosine, 5-methyl-2'-deoxycytosine,
3-methylguanine, and 7-methyladenine gave less than 10%
inhibition.
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FIGURE 2. HPLC separation of deoxyribonucleosides obtained by
enzyme hydrolysis of367 ,ug of DNA isolated from the nasal mu-
cosa ofF344 rats sacrificed 4 hr after IV injection ofNNK (87 mg/
kg body weight). Numbered peaks were identified as follows: (1)
hydrolyzing enzymes; (2) 2'-deoxycytidine; (3) dGuo and thymi-
dine; (4) 2'-deoxyadenosine. The retention volume of 06-MedGuo
underthese conditions is49mL. Thepeak atthisretention volume
corresponds to 5.2 pmole of 06-MedGuo: (--)UV (254 nm);
inhibition of antigen-antibody binding.
The accuracy of BA-ELISA and HPLC-BA-ELISA
methods was compared tothat ofradiochromatographic
and HPLC-fluorimetric methods. Calfthymus DNA was
methylated with [14CH3]N-methyl-N-nitrosourea and
analyzed by the four methods. The methods agree well
with each other, givingcorrelation coefficients by linear
regression analysis greater than 0.99.
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FIGURE 3. Metabolic activation of NNK to methylating intermediates by target tissues of F344 rats. Structures in brackets are hypothetical
intermediates.
The metabolic pathways of NNK are illustrated in
Figure 3. Carbonyl reduction of NNK gives NNA1. As
with most N-nitrosamines, hydroxylation ofthe carbon
a to the N-nitroso group of NNK and NNAI could be
considered acrucial and rate-limiting stepintheirbioac-
tivation to alkylating species. For instance, a-methyl-
ene hydroxylation ofNNK and NNAI would lead to the
generation of methyldiazohydroxide (7). The keto acid
and hydroxy acid (compounds 10 and 11 of Fig. 3) are
two majorurinarymetabolites ofF344 ratstreated with
NNK (17).
The methylating capacities of NNK and NNAI were
compared by culturing rat nasal mucosa with these two
N-nitrosamines. As shown in Table 1, NNK was rapidly
reduced to NNAI in this system. Only 14% ofthe initial
amount ofNNKremained atthe end ofthe 24-hrculture
period. In contrast, NNA1 was not extensively metab-
olized, and 77% of the initial amount remained un-
changed after 24 hr.
Table 1. NNK-NNAI interconversions during culture of rat nasal
mucosa with either NNK or NNA1.
Starting N-nitrosaminea
NNK NNA1
Time of NNK, NNA1, NNK, NNA1
culture, hr nmole/mL nmole/mL nmole/mL nmole/mL
1 440 ± 7 35 ± 5 NDb 480 ± 11
3 323 ± 8 80 ± 5 2.6 ± 0.1 398 ± 10
24 68 ± 9 39 ± 1 4.2 ± 0.3 369 ± 11
aThe initial concentration of NNK or NNA1 was 482 nmole/mL.
Values are mean ± SE obtained from four cultured media.
bND = not detected. Limit of detection is 1.2 nmole/mL.
After24hrofculture, thetotallevelofNNK + NNAI
was 107 nmole/mL and 373 nmole/mL when NNK and
NNA1 were used as starting N-nitrosamines, respec-
tively. TheextentofDNAmethylationwashigherwhen
NNK rather than NNA1 was added to the culture me-
dium (Table 2). With NNA1, DNA methylation after 24
hr was associated with the oxidation of a small fraction
of NNA1 to NNK.
Table 2. Levels of methylation of rat nasal mucosa cultured in
vitro with NNK or NNAI.
Starting N-nitrosaminea
NNK NNA1
06-MeGua, 7-MeGua, 06-MeGua, 7-MeGua,
Time of .mole/mole pumole/mole ,umole/mole ±mole/mole
culture, hr Gua Gua Gua Gua
1 39 600 NDb ND
3 65 1060 ND -c
24 138 - 52.1 745
aMean of two samples of DNA extracted from three nasal septa
each. The initial concentrations of NNK or NNA1 were 482 nmole/
mL.
bNot detected. Limit of detection is 30 ,umole/mole dGuo.
'Not determined.
F344 rats were either treated with a single dose of
NNK and sacrificed 4 hr later or were administered 14
daily doses ofNNK and sacrificed 24 hrlater. As shown
in Table 3, 06-MedGuo was found only in nasal mucosa,
lung and liver.
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Table 3. Susceptibility of F344 rat organs to develop tumors and
levels of 06-MedGuo after treatment with NNK.
06-MedGuo/dGuo, ,umole/moleb
Single dose Multiple dose
Organ Susceptibility' (87 mg/kg)c (40 mg/kg)d
Nasal mucosa + + 219 ± 9.9 7.9 ± 1.4
Lung + + + 13 ± 1.6 11.4 ± 3.8
Liver + 34 ± 2.6 NDe
Kidney - NDf ND
Esophagus - ND ND
Spleen - ND ND
Heart - ND ND
aF344 rats were injected SC with 60 subdoses of NNK during 20
weeks. Total dose was 1 mmole/kg body weight (19).
bValues are mean ± SE (n = 3) as determined by HPLC-BA-
ELISA.
'Five F344 rats were injected IV with a solution of NNK (87 mg/
kg body weight) and were sacrificed 4 hr later.
dTwo F344 rats received eachdaily IPinjections ofNNK (40.3 mg/
kg body weight) for 14 days. The rats were sacrificed 24 hr after the
last injection.
'Level of 7-MeGua/mole Gua as measured by HPLC-fluorimetry
was 1050 ,umole.
fNot detected. Limit of detection was 3 ,umole 06-MedGuo/mole
dGuo.
Discussion
TheBA-ELISAdescribed inthisreportisasensitive,
rapid, and simple method for the detection of06-MedGuo
in DNA modified by methylating agents. The use of
biotin-avidin reagents reduces nonspecific binding of
the second antibody and results in lower background
readings. The BA-ELISA can easily be performed in
one day and does not require the use of radiolabeled
tracers. The sensitivity of BA-ELISA was increased
considerably by chromatographic separation of meth-
ylated and naturally occurring nucleosides obtained by
enzyme hydrolysis.
The HPLC-BA-ELISA is more time-consuming than
the BA-ELISA, taking2daystocomplete, butislimited
in the amount of DNA which can be analyzed only by
the amount ofhydrolyzed DNA which can be loaded on
the HPLC column. In HPLC-fluorimetry it is critical to
achieve good separation ofthe modified nucleobases from
other components that could also fluoresce at the par-
ticular excitation and emission wavelengths used. Good
separation ofthe nucleoside mixture is not as critical in
HPLC-BA-ELISA because ofthe high specificity ofthe
antibody for the carcinogen modified nucleoside.
As shown in Figure 3, reduction ofNNK to NNAI is
amajormetabolic pathway which was observed invivo,
in organ cultures and during incubation of NNK with
rat liver microsomal fraction (3). Interestingly, this re-
duction was also observed in mouse tissue early during
fetal life (18). In human tissues excised from the oral
cavityand upperrespiratorytractand cultured invitro,
reduction ofNNKtoNNAIwas alsothemajormetabolic
pathway. a-Carbon hydroxylation of NNK by cultured
human tissues was also observed, but was not as ex-
tensive as in cultured animal tissue (19).
The reoxidation ofNNAI to NNK was observed with
explants ofA/J mouse lung (atarget tissue ofNNK and
NNAI), although the equilibrium favored NNAI (20).
The ability ofNNK and NNAI to generate methylating
species was compared in cultured rat nasal mucosa (Ta-
ble 1). Levels of 06-MeGua and 7-MeGua were higher
with NNK than with NNA1, suggesting that NNK is
a better substrate for the activating enzymes. This hy-
pothesis was supported by a study of the interconver-
sion of NNK and NNAI by these explants. NNK was
efficiently reduced to NNAI but the reverse reaction
was not favored. Furthermore, the low level of oxida-
tion of NNAI to NNK paralled a low level of DNA
methylation observed with NNAI after24 hrofculture.
These results suggest that NNAI is not associated with
the activation of NNK to DNA methylating species.
NNK, along with NNN and N'-nitrosoanatabine, are
formed byN'-nitrosation ofeithernicotine or anatabine
during curing and/or smoking of tobacco (21,22). All
three N'-nitrosamines induce tumors in F344 rats, but
NNK is the most potent. Even at a dose of 1 mmole/kg
bodyweightNNKinjected SCtomaleF344ratsinduces
ahighpercentageofnasaltumors(74%)andlungtumors
(85%) but a low percentage of liver tumors (11%). In
contrast, NNN induces a lower percentage ofnasal tu-
mors (56%), alow percentage oflungtumors (14%), and
no liver tumors (23).
Aftertreatment ofF344 rats with NNK, methylation
of the DNA at the 06-Gua site was observed only in
organs that develop tumors (Table 3). In NNN-treated
rats no 06-MeGuawas observed in nasal mucosaorliver
DNA. These results suggest that the relatively higher
carcinogenic potency ofNNK compared to NNN could
be due to the formation ofthe promutagenic lesion O6_
MeGua by NNK. However, the formation of other ad-
ducts could also mediate the carcinogenicity of NNK.
A recent mutagenicity study of compounds analogous
to NNK supports this hypothesis (24).
As shown in Figure 3, methyl hydroxylation ofNNK
would lead tothe pyridyloxobutyldiazohydroxide (Com-
pound 5). According to a whole-body autoradiographic
study of rats treated with NNK, alkylation by com-
pound 5 would take place in the mucosa of the ethmo-
turbinates, lateral nasal gland, bronchial mucosa, and
liver (25). Whether compound 5 (Fig. 3) leads to per-
sistent and mispairing adducts is currently being stud-
ied with monospecific antibodies and BA-ELISA.
Methodology developed in the present study will cer-
tainly be instrumental in assessing damage to human
DNA by NNK and other methylating substances pres-
ent in tobacco smoke and chewing tobacco.
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